atezolizumab (Tecentriq®) is accepted for restricted use within NHS Scotland -

atezolizumab (Tecentriq®) is accepted for restricted use within NHS Scotland
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Respiratory disorders
Summary
Monotherapy approved for treatment of adults with locally advanced/metastatic non‑small cell lung cancer after prior chemotherapy. Patients with EGFR activating mutations or ALK +ve tumour mutations should also have received targeted therapy before receiving atezolizumab.
UKMi comment
This advice is contingent upon Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower. Treatment with atezolizumab is subject to a two-year clinical stopping rule.
Related links: